Expertise in
3
conditions

Zhixuan Zhou

2 Yabao Road, 
Beijing, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
2 Yabao Road, 
Beijing, CN 

Overview

Zhixuan Zhou practices practicing medicine in Beijing, China.

Zhou is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Juvenile Dermatomyositis, Dermatomyositis, Polymyositis, and Myositis.

They are actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 2 clinical trials.

Locations

2 Yabao Road, Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: May 12, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

11 Total Publications

Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
Journal: Clinical rheumatology
Published: April 24, 2024

Frequently Asked Questions about Zhixuan Zhou

Is Zhixuan Zhou a top-rated expert for Juvenile Dermatomyositis?

MediFind is an objective health platform that identifies experts based on real-world data. Zhixuan Zhou is classified as an Advanced expert for Juvenile Dermatomyositis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zhixuan Zhou participate in research or clinical trials?

Yes. Zhixuan Zhou has published 11 articles and abstracts on conditions like Juvenile Dermatomyositis. You can view a list of Zhixuan Zhou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile